Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies
BioSpace
Mon, 03/18/24 - 11:25 am
Madrigal Pharmaceuticals
Rezdiffra
NASH
MASH
Madrigal wins FDA approval of first drug for MASH
BioPharma Dive
Thu, 03/14/24 - 06:27 pm
Madrigal Pharmaceuticals
FDA
Rezdiffra
MASH
NASH
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial
Reuters
Wed, 03/13/24 - 10:43 am
Ionis Pharmaceuticals
MASH
NASH
clinical trials
ION224
89bio kicks off Phase III trial for pegozafermin in MASH
Clinical Trials Arena
Tue, 03/12/24 - 06:51 pm
89Bio
clinical trials
pegozafermin
MASH
NASH
Akero, bruised from earlier failure, soars as liver scarring improves in longer MASH trial
Fierce Biotech
Mon, 03/4/24 - 11:21 am
Akero Therapeutics
efruxifermin
MASH
NASH
Boehringer’s survodutide shows monster MASH potential
Pharmaphorum
Mon, 02/26/24 - 10:36 am
Boehringer Ingelheim
weight loss
MASH
NASH
survodutide
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Inventiva Pauses Late-Stage NASH Trial, Keeps Field Open for Madrigal
BioSpace
Fri, 02/16/24 - 11:46 am
Inventiva
NASH
clinical trials
lanifibranor
2 Rising Biotechs That Could Become the Next Novo Nordisk
Motley Fool
Mon, 01/29/24 - 11:04 am
Novo Nordisk
Madrigal Pharmaceuticals
Viking Therapeutics
NASH
Sagimet stock doubles as phase 2b MASH trial hits primary goals, despite dropout queries
Fierce Biotech
Mon, 01/22/24 - 11:06 am
Sagimet Biosciences
clinical trials
MASH
NASH
denifanstat
Novo Nordisk offers 2 Flagship biotechs up to $1B total for obesity, MASH deals
Fierce Biotech
Thu, 01/4/24 - 10:06 am
Novo Nordisk
Omega Therapeutics
Cellarity
Flagship Pioneering
funding
obesity
NASH
MASH
Boehringer bets $2B in biobucks to unlock siRNA targets for NASH treatments
Fierce Biotech
Wed, 01/3/24 - 09:40 am
Boehringer Ingelheim
biobucks
NASH
siRNA
Suzhou Ribo
Ribocure
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
89bio Unveils Bullish Long-Term Data for NASH Candidate
BioSpace
Tue, 11/28/23 - 10:21 am
89Bio
NASH
clinical trials
pegozafermin
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Fierce Biotech
Tue, 10/10/23 - 10:10 am
Akero Therapeutics
NASH
efruxifermin
clinical trials
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
BioSpace
Fri, 09/29/23 - 11:58 am
Madrigal Pharmaceuticals
NASH
resmetirom
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
RTT News
Tue, 09/26/23 - 10:13 am
Intercept Pharma
M&A
Alfasigma
NASH
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Tue, 09/12/23 - 10:34 am
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
Kriya, flush with funding, buys a gene therapy for NASH
BioPharma Dive
Thu, 09/7/23 - 10:51 pm
Kriya Therapeutics
gene therapy
NASH
M&A
Tramontane Therapeutics
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »